KFAS
RYTM icon

Keating Financial Advisory Services’s Rhythm Pharmaceuticals RYTM Stock Holding History

Keating Financial Advisory Services’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$957 Buy
11
+2
+22% +$194 ﹤0.01% 2104
2025
Q4 		$963 Buy
+9
New +$955 ﹤0.01% 1817

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Keating Financial Advisory Services's RYTM Position: Q1 2026 in Review

Keating Financial Advisory Services increased its Rhythm Pharmaceuticals (RYTM) stake by 22% in Q1 2026, buying an estimated $194 and bringing the position to 11 shares worth $957. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Keating Financial Advisory Services first reported a position in RYTM in Q4 2025 and has held it in 2 quarters since. The position peaked at $963 in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Keating Financial Advisory Services held 11 shares of Rhythm Pharmaceuticals worth $957 as of Q1 2026.
  • Keating Financial Advisory Services bought 2 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $194.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q1 2026, its #2104 holding.
  • Keating Financial Advisory Services first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Rhythm Pharmaceuticals position peaked at $963 in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Keating Financial Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.